News for Immunocore Holdings Stock (IMCR)

Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know

Zacks Investment Research • Friday

Immunocore to present at upcoming investor conferences

GlobeNewsWire • Friday

Immunocore reports third quarter financial results and provides a business update

GlobeNewsWire • Wednesday

Immunocore (IMCR) Upgraded to Buy: Here's Why

Zacks Investment Research • Tuesday

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

GlobeNewsWire • 09/14/24

Immunocore to present at the 2024 Cantor Global Healthcare Conference

GlobeNewsWire • 09/12/24

Immunocore: Pipeline Expands HLA Tumor Targeting Beyond Kimmtrak

Seeking Alpha • 08/30/24

Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal

Seeking Alpha • 08/12/24

Immunocore Holdings plc (IMCR) Q2 2024 Earnings Call Transcript

Seeking Alpha • 08/11/24

3 Small-Cap Stocks with Significant Growth Potential

InvestorPlace • 08/06/24

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

GlobeNewsWire • 06/01/24

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

GlobeNewsWire • 05/31/24

Immunocore to present at the Jefferies Global Healthcare Conference

GlobeNewsWire • 05/30/24

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

GlobeNewsWire • 05/29/24

Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.

Barrons • 05/24/24

Immunocore reports first quarter financial results and provides a business update

GlobeNewsWire • 05/08/24

Immunocore announces upcoming presentation and posters at ASCO 2024

GlobeNewsWire • 04/24/24

Billionaire's Biotech Bets: 3 Stocks Dominating Bill Gates' Portfolio

InvestorPlace • 03/13/24

Immunocore presented two posters at CROI 2024

GlobeNewsWire • 03/05/24

Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript

Seeking Alpha • 02/28/24

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

GlobeNewsWire • 02/28/24

Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial

GlobeNewsWire • 02/22/24

Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

GlobeNewsWire • 02/21/24

5 Biotech Stocks to Consider for Your Portfolio in 2024

Zacks Investment Research • 02/13/24

Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?

Zacks Investment Research • 02/01/24